(Q46885882)

26 December 2017

title

Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value (English)

1 reference

26 December 2017

main subject

Gram-negative bacteria

0 references

1 reference

1 reference

3

Helio S Sader

1 reference

26 December 2017

1

Robert K Flamm

1 reference

26 December 2017

4

Ronald N Jones

1 reference

26 December 2017

author name string

Gregory G Stone

series ordinal

2

1 reference

26 December 2017

Wright W Nichols

series ordinal

5

1 reference

26 December 2017

publication date

6 December 2013

1 reference

26 December 2017

published in

Journal of Chemotherapy

1 reference

26 December 2017

volume

26

1 reference

26 December 2017

issue

6

1 reference

26 December 2017

page(s)

333-338

1 reference

26 December 2017

Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor

cites work

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

New β-lactam-β-lactamase inhibitor combinations in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized stud

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

Normalized resistance interpretation as a tool for establishing epidemiological MIC susceptibility breakpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

Chromosomal cephalosporinases responsible for multiple resistance to newer beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947813Y.0000000145

10.1179/1973947813Y.0000000145

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017